Skip Navigation


Annals of Oncology Advance Access originally published online on September 11, 2009
Annals of Oncology 2009 20(11):1898-1899; doi:10.1093/annonc/mdp431
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/11/1898    most recent
mdp431v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Trojan, A.
Right arrow Articles by Kristiansen, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trojan, A.
Right arrow Articles by Kristiansen, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Successful PDGFR-{alpha}/β targeting with imatinib in uterine sarcoma

The first 10% of the full text of this article appears below.

Uterine sarcomas are a heterogeneous group of neoplasms with a propensity for metastasis and resistance to conventional therapy and represent 8% of all uterine malignancies. They consist of pure stromal tumors, the endometrial stromal sarcomas (ESSs) and leiomyosarcomas, mixed epithelial and mesenchymal tumors and carcinosarcomas [1]. The poor prognosis of uterine sarcomas is due, in part, to the limited success of treatments meant to enhance local and distant disease control after surgical resection. Response to . . . [Full Text of this Article]

A. Trojan1,*, M. Montemurro2, M. Kamel3 and G. Kristiansen4

1 OnkoZentrum Zürich, Klinik im Park, Zürich
2 Centre Pluridisciplinaire d'Oncologie
3 Department of Radiology, Lausanne
4 Department of Pathology, University Hospital, Zürich, Switzerland

* (E-mail: trojan@1st.ch)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?